ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: BioSpecifics Technologies Corp. (BSTC) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

BioSpecifics Technologies Corp. (BSTC)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: MNOV,PIP,MDVN,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

BioSpecifics Technologies Corp.© quotemedia

Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.